A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center

World Journal of Urology

Volumn 32, Issue 4, 2014, Pages 891-897

  Becker, Andreas ^a   Seiler, Daniel ^b   Kwiatkowski, Maciej ^b,d   Kluth, Luis Alex ^a   Schnell, Dietrich ^c   Graefen, Markus ^a   Schlomm, Thorsten ^a   Fisch, Margit ^a   Recker, Franz ^b   Weissbach, Lothar ^c   Chun, Felix K H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Martini Clinic Prostate Cancer Center Hamburg Eppendorf ^*  (Switzerland)

^c Stiftung Maennergesundheit   (Germany)

^d Academic Hospital Braunschweig   (Germany)

Author keywords

Active surveillance; Deferred treatment; Prostate cancer; Radical prostatectomy; Radiotherapy

Indexed keywords

AGED; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNITY CARE; COMPARATIVE STUDY; GERMANY; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SWITZERLAND; TERTIARY CARE CENTER; TREATMENT OUTCOME; WATCHFUL WAITING;

AGED; COHORT STUDIES; COMMUNITY HEALTH SERVICES; GERMANY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SWITZERLAND; TERTIARY CARE CENTERS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84905034668     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1309-2     Document Type: Article

References (23)

1. Measurement of progress against cancer (1990) Extramural committee to assess measures of progress against cancer. J Natl Cancer Inst 82(10): 825-835.
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1): 11-30.
3. Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3): 203-213.
4. Bill-Axelson A, Holmberg L, Ruutu M et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18): 1708-1717.
5. Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29(27): 3669-3676.
6. Tosoian JJ, Trock BJ, Landis P et al (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29(16): 2185-2190.
7. van den Bergh RC, Roemeling S, Roobol MJ et al (2009) Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55(1): 1-8.
8. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28(1): 126-131.
9. Graefen M, Schlomm T (2013) Active surveillance for low-risk prostate cancer: some questions are answered, but many questions remain. Eur Urol 63(4): 604-605.
10. Bul M, Zhu X, Valdagni R et al (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4): 597-603.
11. Steginga SK, Turner E, Donovan J (2008) The decision-related psychosocial concerns of men with localised prostate cancer: targets for intervention and research. World J Urol 26(5): 469-474.
12. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178(3 Pt 2): S14-S19.
13. van den Bergh RC, Vasarainen H, van der Poel HG et al (2010) Short-term outcomes of the prospective multicentre 'prostate cancer research international: active surveillance' study. BJU Int 105(7): 956-962.
14. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13): 1320-1328.
15. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A (2004) A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59(2): 380-385.
16. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5): 368-374.
17. Bul M, van den Bergh RC, Zhu X et al (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110(11): 1672-1677.
18. Whitson JM, Porten SP, Hilton JF et al (2011) The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 185(5): 1656-1660.
19. Lu-Yao GL, Albertsen PC, Moore DF et al (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302(11): 1202-1209.
20. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(3 Suppl): 933-938.
21. Bul M, Zhu X, Rannikko A et al (2012) Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 62(2): 195-200.
22. Pierorazio PM, Spencer BA, McCann TR, McKiernan JM, Benson MC (2007) Preoperative risk stratification predicts likelihood of concurrent PSA-free survival, continence, and potency (the trifecta analysis) after radical retropubic prostatectomy. Urology 70(4): 717-722.
23. Gillitzer R, Hampel C, Thomas C et al (2009) Therapy choices of German urologists and radio-oncologists if personally diagnosed with localized prostate cancer. Urologe A 48(4): 399-407.